✨ Your Portfolio is fetched and updated from zerodha.
Mid Pharmaceuticals

Alkem Laboratories Ltd.

ALKEM

Get real time AI alerts about this company on your WhatsApp!
Market Cap
₹66,931 Cr.
P/E
28.35

Alkem Laboratories Ltd.

  • Alkem Laboratories
  • Aurobindo Pharma
  • Abbott India
  • TJI Pharma

FAQs on Alkem Laboratories Ltd. Shareprice

Alkem Laboratories has given lower returns compared to its competitors.
Alkem Laboratories has grown at ~8.85% over the last 2yrs while peers have grown at a median rate of 20.74%

Alkem Laboratories is expensive when considering the EV/EBIDTA, however latest PE is < 3 yr avg PE.
Latest PE of Alkem Laboratories is 28.81, while 3 year average PE is 31.61.
Also latest EV/EBITDA of Alkem Laboratories is 24.35 while 3yr average is 24.06.

View FAQ's On Business

Growth Table

  • Alkem Laboratories Ltd.
  • Aurobindo Pharma
  • Abbott India

Balance Sheet

  • Alkem Laboratories Ltd.
  • Aurobindo Pharma
  • Abbott India

Balance Sheet Snapshot

No data available.

Fund Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end

Profit & Loss

  • Alkem Laboratories Ltd.
  • Aurobindo Pharma
  • Abbott India

Cash Flow

  • Alkem Laboratories Ltd.
  • Aurobindo Pharma
  • Abbott India

Cash Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.

Ratios

= Dominant Factor
  • Alkem Laboratories Ltd.
  • Aurobindo Pharma
  • Abbott India

Quarterly Results

  • Alkem Laboratories Ltd.
  • Aurobindo Pharma
  • Abbott India

Reverse DCF

locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF

FAQs on Alkem Laboratories Ltd. Financials

Balance sheet of Alkem Laboratories is strong.
It shouldn't have solvency or liquidity issues.

Yes, The net debt of Alkem Laboratories is increasing.
Latest net debt of Alkem Laboratories is ₹414 Crs as of Sep-25.
This is greater than Mar-25 when it was -₹1,993.61 Crs.

Yes, profit is increasing.
The profit of Alkem Laboratories is ₹2,412 Crs for TTM, ₹2,165 Crs for Mar 2025 and ₹1,796 Crs for Mar 2024.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Alkem Laboratories latest dividend payout ratio is 24.84% and 3yr average dividend payout ratio is 37.4%

Companies resources are majorly tied in miscellaneous assets

View FAQ's On Shareholding
Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech